A study suggested that intravenous injection of the P2X3 antagonist AF-353 decreased the frequency of sensory field potentials evoked by activation of bladder noxious pathways and decreased the frequency of nonvoiding contractions in rats with neurogenic bladder hyperactivity [22]. The gene discussed is P2RX3; the disease is carcinoma.